These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b. Hashimoto Y; Ochi H; Abe H; Hayashida Y; Tsuge M; Mitsui F; Hiraga N; Imamura M; Takahashi S; Nelson Hayes C; Ohishi W; Kubo M; Tsunoda T; Kamatani N; Nakamura Y; Chayama K J Med Virol; 2011 Jun; 83(6):981-8. PubMed ID: 21503910 [TBL] [Abstract][Full Text] [Related]
9. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin. Bonardi R; Tabone M; Manca A; Pellicano R; Ciancio A; Rizzetto M Biomed Pharmacother; 2011 Jul; 65(4):303-6. PubMed ID: 21723079 [TBL] [Abstract][Full Text] [Related]
10. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women. Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817 [TBL] [Abstract][Full Text] [Related]
11. High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial). Chevaliez S; Hézode C; Soulier A; Costes B; Bouvier-Alias M; Rouanet S; Foucher J; Bronowicki JP; Tran A; Rosa I; Mathurin P; Alric L; Leroy V; Couzigou P; Mallat A; Charaf-Eddine M; Babany G; Pawlotsky JM Gastroenterology; 2011 Jul; 141(1):119-27. PubMed ID: 21439960 [TBL] [Abstract][Full Text] [Related]
12. Low-dose pegylated interferon-α2a plus ribavirin therapy for elderly and/or cirrhotic patients with HCV genotype-1b and high viral load. Tamai H; Mori Y; Shingaki N; Kawashima A; Tsukuda H; Higashi K; Moribata K; Kawaguchi M; Ueda K; Deguchi H; Inoue I; Maekita T; Iguchi M; Kato J; Ichinose M Antivir Ther; 2014; 19(1):107-15. PubMed ID: 24162072 [TBL] [Abstract][Full Text] [Related]
13. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Liu CH; Huang CF; Liu CJ; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Chen SI; Lin JW; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH Ann Intern Med; 2013 Dec; 159(11):729-38. PubMed ID: 24297189 [TBL] [Abstract][Full Text] [Related]
14. Combination therapy with silibinin, pegylated interferon and ribavirin in a patient with hepatitis C virus genotype 3 reinfection after liver transplantation: a case report. Knapstein J; Wörns MA; Galle PR; Zimmermann T J Med Case Rep; 2014 Jul; 8():257. PubMed ID: 25047566 [TBL] [Abstract][Full Text] [Related]
15. Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients. Katz LH; Goldvaser H; Gafter-Gvili A; Tur-Kaspa R Cochrane Database Syst Rev; 2012 Sep; (9):CD008516. PubMed ID: 22972122 [TBL] [Abstract][Full Text] [Related]
16. Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial. Manns M; Reesink H; Berg T; Dusheiko G; Flisiak R; Marcellin P; Moreno C; Lenz O; Meyvisch P; Peeters M; Sekar V; Simmen K; Verloes R Antivir Ther; 2011; 16(7):1021-33. PubMed ID: 22024518 [TBL] [Abstract][Full Text] [Related]
17. Safety and effectiveness of response-guided therapy using pegylated interferon and ribavirin for chronic hepatitis C virus infection in patients on maintenance dialysis. Goel A; Bhadauria DS; Kaul A; Prasad N; Gupta A; Sharma RK; Rai P; Aggarwal R Nephrology (Carlton); 2017 Sep; 22(9):706-711. PubMed ID: 27286895 [TBL] [Abstract][Full Text] [Related]
18. A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin. Selvapatt N; Habibi MS; Brown A J Med Virol; 2015 Oct; 87(10):1716-21. PubMed ID: 25914248 [TBL] [Abstract][Full Text] [Related]
19. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lawitz E; Lalezari JP; Hassanein T; Kowdley KV; Poordad FF; Sheikh AM; Afdhal NH; Bernstein DE; Dejesus E; Freilich B; Nelson DR; Dieterich DT; Jacobson IM; Jensen D; Abrams GA; Darling JM; Rodriguez-Torres M; Reddy KR; Sulkowski MS; Bzowej NH; Hyland RH; Mo H; Lin M; Mader M; Hindes R; Albanis E; Symonds WT; Berrey MM; Muir A Lancet Infect Dis; 2013 May; 13(5):401-8. PubMed ID: 23499158 [TBL] [Abstract][Full Text] [Related]
20. Pegylated interferon-α monotherapy leads to low response rates in HIV-infected patients with acute hepatitis C. Arends JE; van Assen S; Stek CJ; Wensing AM; Fransen JH; Schellens IM; Spijkers SN; Mudrikova T; van Baarle D; Sprenger HG; Hoepelman AI Antivir Ther; 2011; 16(7):979-88. PubMed ID: 22024513 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]